Evaluation and Treatment of Hypercholesterolemia

Abstract

Get full access to this article

View all access options for this article.

References

The Expert Panel. Report of the National Cholesterol Education Program expert panel on detection, evaluation and treatment of high blood cholesterol in adults. Arch Intern Med 148:36-39, 1988

Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. National Cholesterol Education Program. NHLBI, HHS. NIH Publication No 88-2925, January 1988, pp 1-87

Fredrickson DS , Levy RI , Lees RS : Fat transport in lipoproteins. An integrated approach to mechanisms and disorders. N Engl J Med 276:34-44, 94-104, 148-156, 215-225, 273-281, 1967

Schafer EJ , Levy RI : Pathogenesis and management of lipoprotein disorders. N Engl J Med 312:1300-1310, 1985

Gag A. , Grundy SM : Lovastatin for lowering cholesterol levels in non-insulin-dependent diabetes mellitus. N Engl J Med 318:81-86, 1988

Dayton S. , Pearce ML , Hasimoto S. , et al: A controlled clinical trial of a diet high in unsaturated fat in preventing complications of atherosclerosis. Circulation 40(suppl II):111-163, 1969

Glauber H. , Wallace P. , Griver K. , et al: Adverse metabolic effect of omega-3 fatty acids in non-insulin-dependent diabetes mellitus. Ann Intern Med 108:663-668, 1988

Anderson JW , Zettwoch N. , Feldman T. , et al: Cholesterol-lowering effect of psyllium hydrophilic mucilloid for hypercholesterolemic men. Ann Intern Med 148, 292-296, 1988

Hegsted DM , McGandy RB , Myers ML , et al: Quantitative effects of dietary fat on serum cholesterol in man. Am J Clin Nutr 17:281-295, 1965

10.

Brensike JF , Levy RI , Kelsey SF , et al: Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: Results of the NHLBI Type II Coronary Intervention Study. JAMA 69:313-324, 1984

11.

Blankenhorn DH , Nessim SA , Johnson RL , et al: Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 257:3233-3240, 1987

12.

Brown WV , Goldberg IJ , Ginsberg HN : Treatment of common lipoprotein disorders. Prog Cardiovasc Dis 27:1-20, 1984

13.

Perry RS : Contemporary recommendations for evaluating and treating hyperlipidemia. Clin Pharm 5:113-127, 1986

14.

Illingworth DR : Lipid-lowering drugs. An overview of indications and optimum therapeutic use. Drugs 33:259-279, 1987

15.

Knodel LC , Talbert RL : Adverse effects of hypolipidaemic drugs. Med Toxicol 2:10-32, 1987

16.

Crouse JR III: Hypertriglyceridemia: A contraindication to the use of bile acid binding resins. Am J Med 243-248, 1987

17.

Malloy MJ , Kane JP , Kunitake ST , et al: Complementarity of colestipol, niacin, and lovastatin in treatment of severe hypercholesterolemia. Ann Intern Med 107:616-623, 1987

18.

Lipid Research Clinics Program : The Lipid Research Clinics Coronary Primary Prevention Trial Results: I. Reduction in the incidence of coronary heart disease. JAMA 251:351-364, 1984

19.

Lipid Research Clinics Program : The Lipid Research Clinics Coronary Primary Prevention Trial Results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 251:365-374, 1984

20.

Schaefer MJ , Jungnickel PW , Jacobs EW , et al: Acceptability of cholestyramine or colestipol combinations in six vehicles. Clin Pharm 6:51-54, 1987

21.

Coronary Drug Project Research Group : Clofibrate and niacin in coronary heart disease. JAMA 231:360-381, 1975

22.

Olsson AG , Carlson LA , Anggard E. , et al: Prostaglandin production augmented in the short term by nicotinic acid. Lancet 2:565-567, 1983

23.

Sigroth K. : Effect of clonidine on nicotinic acid flushing. Lancet 2:58, 1974

24.

Krukemeyer JJ , Talbert RL : A new cholesterol-lowering agent. Pharmacotherapy 7:198-210, 1987

25.

McKenney J. : Lovastatin: A new cholesterol lowering agent. Clin Pharm 7:21-36, 1988

26.

Tobert JA : New developments in lipid-lowering therapy. The role of inhibitors of hydroxymethylglutaryl-coenzyme A reductase. Circulation 76:534-538, 1987

27.

Lovastatin Study Group II : Therapeutic response to lovastatin (mevinolin) in nonfamilial hypercholesterolemia. A multicenter trial. JAMA 256:2829-2834, 1986

28.

Norman DJ , Illingworth DR , Munson J. , et al: Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin. N Engl J Med 318:46-47, 1988

29.

East C. , Aliviatos PA , Grundy SM , et al: Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation. N Engl J Med 318:47-48, 1988

30.

Committee of Principle Investigators : A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Br Heart J 40:1019-1118, 1978

31.

Frick MH , Elo O. , Haapa K. , et al: Helsinki Heart Study: Primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317:1237-1245, 1987

32.

Canner PL , Berge KG , Wenger NK , et al: Fifteen year mortality in Coronary Drug Project patients: Long-term benefit with niacin. J Am Coll Cardiol 1245-1255, 1986

33.

Havel RJ , Hunninghake DB , Illingworth DR , et al: Lovastatin (Mevinolin) in the treatment of heterozygous familial hypercholesterolemia. Ann Intern Med 107:609-615, 1987

34.

Illingworth DR : Mevinolin (lovastatin) plus colestipol in therapy for severe heterozygous familial hypercholesterolemia. Ann Intern Med 101:598-604, 1984

35.

Knopp RH , Ginsberg J. , Albers JJ , et al: Contrasting effects of unmodified and timed-release forms of niacin on lipoproteins in hyperlipidemic subjects: Clues to mechanism of action of niacin. Metabolism 34:642-650, 1985

36.

Taylor WC , Pass TM , Shepard DS , et al: Cholesterol reduction and life expectancy. A model incorporating multiple risk factors. Ann Intern Med 106:605-614, 1987